INCYTE CORP
Analysts reiterated Buy ratings on Immunic (IMUX) with a $29 target, Incyte (INCY) with a $150 target, and Eli Lilly (LLY) with a $1600 target. Consensus targets suggest 167.5%, 6.6%, and 19.1% upside respectively.
Incyte (INCY) agreed with CMS to align Medicaid prices of Jakafi and Jakafi XR with international benchmarks, improving affordability. The deal may exempt Incyte from future CMS pricing mandates. The company expects no impact on 2026 guidance. Jakafi is a key revenue driver for Incyte, making this agreement significant for investors.
Incyte has reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to enhance access to its medicines. The deal aims to improve patient access to Incyte's treatments, according to the company.
Over the past 7 days, alphai's AI scored 5 news stories mentioning INCY (INCYTE CORP). Coverage has skewed bullish: 4 bullish, 1 neutral, and 0 bearish.
Recent INCY coverage spans regulation, earnings and financial news.
In the last 30 days, INCY insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($2.7M). The most active reporter was CAGNONI PABLO J, President, Global Head of R&D, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Target implies ~22% upside from last close.
The agreement may protect revenue by avoiding stricter pricing mandates while modestly reducing Medicaid margins.
The CMS partnership could boost sales and market perception of Incyte's pipeline.
Guidance upgrade signals stronger near‑term revenue growth and may drive the stock higher.
Strong earnings and cash flow support continued buy‑and‑hold positioning; upcoming data could add upside.
alphai scores every news story that mentions INCY with an AI model for sentiment and relevance, and aggregates insider trades from INCYTE CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts reiterated Buy ratings on Immunic (IMUX) with a $29 target, Incyte (INCY) with a $150 target, and Eli Lilly (LLY) with a $1600 target. Consensus targets suggest 167.5%, 6.6%, and 19.1% upside respectively.
2 min readIncyte (INCY) agreed with CMS to align Medicaid prices of Jakafi and Jakafi XR with international benchmarks, improving affordability. The deal may exempt Incyte from future CMS pricing mandates. The company expects no impact on 2026 guidance. Jakafi is a key revenue driver for Incyte, making this agreement significant for investors.
2 min readIncyte has reached an agreement with the Centers for Medicare & Medicaid Services (CMS) to enhance access to its medicines. The deal aims to improve patient access to Incyte's treatments, according to the company.
1 min readJosh Brown, CEO of Ritholtz Wealth Management, highlighted Incyte (INCY) and Biogen (BIIB) as top stock picks, focusing on healthcare over AI. Incyte's stock is up 22% this year, with strong earnings and a growing drug pipeline. The company reported 38% revenue growth and raised its 2026 sales guidance. Risks include Jakafi's patent expiration and competition for Opzelura.
2 min readIncyte (INCY) and Revolution Medicines (RVMD) are competing in the KRAS inhibitor market. RBC noted INCY's upcoming ESMO data for its KRAS G12D inhibitor, while Bernstein raised RVMD's price target. RVMD received FDA approval for Rasonque. INCY reported Q2 2026 revenue of $1.67B, while RVMD had no product revenue but $3.9B in cash. Institutional investors favor RVMD, with notable holdings by Farallon Capital and Baker Bros. Advisors.
3 min readIncyte (INCY) reported Q2 2026 earnings and revenue above expectations, driven by strong demand for Jakafi and Opzelura. The company raised its 2026 net product revenue guidance and received FDA approval for Niktimvo, adding a new therapy to its portfolio. Analysts project varying revenue and earnings estimates for 2029, with the company targeting $5.8 billion in revenue and $1.1 billion in earnings, while the lowest estimates predict $5.4 billion in revenue and $1.2 billion in earnings.
2 min readCAGNONI PABLO J (President, Global Head of R&D) sold 10,801 shares of INCYTE CORP (INCY) at $125.56 ($1.36M total) on 2026-08-19 under a Rule 10b5-1 trading plan.
1 min readWall Street analysts issued upgrades, downgrades, and initiations for several companies. Upgrades include Analog Devices (ADI) to Outperform at Bernstein, Etsy (ETSY) to Buy at Bank of America, and Merck & Co (MRK) to Overweight at Morgan Stanley. Downgrades include Allstate (ALL) to Underperform at Keefe Bruyette and TJX Companies (TJX) to Neutral at Citigroup. Initiations include Alphabet (GOOGL) and Shopify (SHOP) with Buy ratings at Rosenblatt.
3 min readIncyte (INCY) raised its 2026 revenue forecast to $5.13B-$5.26B after a CMS settlement. Q2 2026 net sales rose 40% to $1.49B, and adjusted EPS was $3.09, beating estimates. Analysts expect FY 2026 EPS to decrease 52.7% YoY to $2.64. The stock has a 'Moderate Buy' consensus rating, with a mean price target of $127.09.
2 min readCAGNONI PABLO J (President, Global Head of R&D) sold 10,803 shares of INCYTE CORP (INCY) at $120.04 ($1.30M total) on 2026-08-12 under a Rule 10b5-1 trading plan.
2 min read
